Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Main finding · New-onset goutResult — go to the resultHazard ratio 0.49 95% CI 0.42–0.58Authors' conclusion
SGLT2I use was associated with lower risks of new gout diagnosis compared with DPP4I use.
Study context
- Population
- Patients with type-2 diabetes mellitus treated with SGLT2I or DPP4I, 1 January 2015 to 31 December 2020, Hong Kong (median age 63.23 years; 53.74% males)median follow-up 5.59 years
- Participants
- 43,201 patients
- Exposure
- SGLT2I vs DPP4I
- SGLT2In = 16,144
- DPP4In = 27,057reference
- Outcome
- New-onset gout
Methodological detailspopulation-based, propensity score matching (1:1), multivariable Cox regression, competing risks models
- Population-based
- Propensity score matching (1:1)
- Multivariable Cox regression
- Competing risks models
Main finding
As reported in the abstract
Hazard ratio
0.49
95% CI 0.42–0.58
P < 0.0001
By group
SGLT2I
2.5
95% CI 2.2–2.9
DPP4I
5.2
95% CI 4.8–5.8
SGLT2Ivs DPP4I
HR 0.49 (95% CI 0.42–0.58); P < 0.0001
Observational data: associations, not effects.
Original publication
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes. Rheumatology (Oxford). Published 6 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →